105803-40-5

Upstream product

• 115224-53-8 (1S,2S,4R,7S)-spiro(3-oxatricyclo<5.2.0.0^2,4>nonane-8,2'-<1,3>dioxolane) 
• 105803-39-2 (S)-3-<(tert-Butyldimethylsilyl)oxy>-3-cyclohexyl-1-propyne 
• 97563-45-6 1-cyclohexylprop-2-yn-1-ol 
• 7560-69-2 1-cyclohexyl-2-propyn-1-one 
• 91098-88-3 (3S)-3-(tert-butyldimethyl-siloxy)-3-cyclohexylprop-1-yne 
• 108104-19-4 (+/-)-spiro(bicyclo<4.2.0>oct-2-ene-7,2'-<1,3>dioxolane) 
• 2043-61-0 cyclohexanecarbaldehyde 
• 115224-54-9 C₁₂H₂₀O₄ 
• 115150-89-5 (1R,6S,7S)-8,8-dichlorobicyclo<4.2.0>oct-2-en-7-ol 
• 115224-52-7 (1R,6S)-8,8-dichlorobicyclo<4.2.0>oct-2-en-7-one 
• 52466-04-3 (1R,6S)-bicyclo<4.2.0>oct-2-en-7-one 
• 51592-71-3 8,8-dichlorobicyclo<4.2.0>oct-2-en-7-one 
• 105880-44-2 C₂₅H₄₂O₄Si 
• 105880-38-4 (1S)-1-cyclohexyl-2-propyn-1-ol 

Downstream Products

• 105803-42-7 (3'S,1S,2S,3R,6S)-2-(3'-cyclohexyl-3'-hydroxyprop-1'-ynyl)-3-hydroxybicyclo<4.2.0>octan-7-one 
• 105880-50-0 4-[(1S,2S,3R,6S)-2-((S)-3-Cyclohexyl-3-hydroxy-prop-1-ynyl)-3-hydroxy-bicyclo[4.2.0]oct-(7E)-ylidene]-butyric acid 
• 105284-21-7 butanoic acid, 4-[(1S,2S,3R,6S)-2-[(3S)-3-cyclohexyl-3-hydroxy-1-propynyl]-3-hydroxybicyclo[4.2.0]oct-7-ylidene]-(4Z) 

Relevant academic research and scientific papers

Application of Bakers' Yeast Mediated Reductions of Bicyclooct-2-en-7-ones to the Enantioselective Synthesis of Prostacyclin Analogues

Reduction of 8,8-dichlorobicyclooct-2-en-7-one (14) with bakers' yeast gave (1R,6S,7S)-8,8-dichlorobicyclooct-2-en-7-ol and (1S,6R)-8,8-dichlorobicyclooct-2-en-7-one in high optical purities and 27percent and 14perce

Potent Prostacyclin Analogues Based on the Bicyclooctane Ring System

The novel and biologically active prostacyclin mimetics 2 and 29 were prepared in a sequence based on the regioselective opening of epoxide 7 with a lithium acetylide in the presence of boron trifluoride etherate.The regioselectivity of epoxide opening wa

Novel [4,2,0]bicyclooctane derivatives with valuable therapeutic properties

Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension, and atherosclerosis are compounds depicted in formulas (1), (2), and (3): STR1 wherein: n is 2 or 3; R1 is CH2 OH, CHO, CO2 R or CO2 H; R2 is hydrogen or methyl; and R3 is linear or branched alkyl having 5-10 carbon atoms, STR2 optionally substituted with lower alkyl, lower alkoxy, trifluoromethyl, or halogen, in which a is 0, 1 or 2; b is 3-7; m is 1 or 2; and R is STR3 in which each R4 is independently hydrogen or lower alkyl having 1-6 carbon atoms, and the pharmaceutically acceptable, non-toxic salts and esters thereof.